Form 4 for JNJ Johnson & Johnson
Accepted 2025-10-20 19:13:56 ET · period of report 2025-10-17 · accession 0000200406-25-000204 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-20 19:13 | 2025-10-17 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $157.92 | +21.7K | 32.4K | +204% | +$3.43M |
| D | 2025-10-20 19:13 | 2025-10-17 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | S - Sale+OE | $192.71 | -21.7K | 10.7K | -67% | -$4.19M |
| D | 2025-10-20 19:13 | 2025-10-17 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $157.92 | -21.7K | 43.4K | -33% | -$3.43M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-17 | M | A | 21,721 | $157.92 | 32,379 | D | — | — | |
| 2 | Common | Common Stock | 2025-10-17 | S | D | 21,721 | $192.71 | 10,658 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $192.69 to $192.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Derivative | Employee Stock Options (Right to Buy) | 2025-10-17 | M | D | 21,721 | $157.92 | 43,442 | D | $157.92 · — to 2034-02-15 | 21,721 Common Stock | (F2) Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. |